“Machine learning is helping food companies reformulate products, strengthen allergen control and personalize nutrition while some manufacturers report four- to five-fold faster R&D and expand investment in AI-enabled production, quality inspection and supply-chain intelligence.”

Boston, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is fundamentally redefining how the global gluten-free food industry operates — accelerating R&D timelines, hardening supply chains against commodity volatility, and enabling a new generation of personalized nutrition platforms. A new report from BCC Research, AI Impact on Gluten Free Products - BCC Pulse Report (AIT193A), maps the full scope of AI's strategic footprint across the gluten-free value chain, from molecular formulation engines to agentic commerce and ESG-aligned lifecycle assessment.

Key Findings

• Investment intensity is accelerating despite macroeconomic headwinds. Dr. Schär closed 2025 with a global turnover of $721.5 million and committed an additional $31.9 million for 2026 to expand AI-integrated production capacity across Italy, Spain, and Germany. Kewpie Corporation is investing approximately $24 million in a new AI-powered food processing plant in India, incorporating deep learning visual inspection systems for allergen and gluten-free production. AI is demonstrably cutting R&D timelines by 30% to 40%, with Mondelēz International reporting a 4x to 5x acceleration in R&D speed using machine learning.
• Asia-Pacific leads in AI adoption velocity. Rapid urbanization in India and China, an aging population in Japan, and accelerating digital commerce expansion position Asia-Pacific as the fastest-growing market for AI adoption in the gluten-free sector. National digital transformation programs — including Saudi Vision 2030 and APAC e-commerce infrastructure build-outs — are amplifying institutional demand for AI-enabled free-from food capabilities.
• The strategic paradigm has shifted from gluten removal to functional optimization. In 2026, the industry's AI investment focus moved decisively away from mere gluten avoidance toward enhancing protein content, fiber levels, and glycemic index in gluten-free staples. NotCo's proprietary 'Giuseppe' AI platform — now licensed to CPG partners — analyzes thousands of plant-ingredient combinations to replicate wheat-based food profiles at the molecular level, enabling faster and more nutritionally complete substitution modeling.
• Clean-label mandates and microbiome analytics are converging. Consumer demand for gluten-free products free of synthetic thickeners and artificial additives is being met through AI-driven natural formulation. Simultaneously, platforms such as Viome Life Sciences and Spoon Guru are integrating microbiome sequencing and metabolic markers to deliver personalized gluten-free dietary planning — creating subscription-based revenue models anchored in individual health data.
• Emerging technology deployment is broad and deepening. Hyperspectral imaging (Specim/ImpactVision), Puratos's Digi-Eye and Pannovate crumb-structure analysis, dual-energy X-ray AI software (Eagle Product Inspection), and General Mills's AI-powered digital personas collectively represent a maturing technology stack that spans quality control, product prototyping, and consumer sentiment analytics. Agthia Group's 2025 partnership with Microsoft to deploy AI across product development and supply chain signals enterprise-level institutional commitment to AI in the free-from category.
• Key players shaping the competitive landscape include Dr. Schär, General Mills, Mondelēz International, Nestlé, Barilla Group, NotCo, Kewpie Corporation, Agthia Group, Camil Alimentos, M. Dias Branco, Viome Life Sciences, Spoon Guru, Puratos, and Shiru, among others.

Strategic Implications

The structural case for AI in gluten-free food production is driven by compounding operational pressures that no single conventional solution can address simultaneously. Gluten's viscoelastic properties remain technically difficult to replicate — removal produces crumbly textures, sandy mouthfeel, and accelerated staling in baked goods. Meanwhile, the specialty raw materials that underpin gluten-free formulation — teff, quinoa, almond flour — are subject to climate-related crop failures and persistent currency volatility, particularly in South American and MEA markets. AI-driven predictive supply chain tools are becoming essential infrastructure for managing this input risk.
On the compliance side, maintaining certified gluten-free status at below 20 parts per million across FDA, EFSA, and multiple additional jurisdictions demands continuous, non-destructive safety monitoring — a capability that traditional batch testing cannot cost-effectively deliver. AI-powered continuous monitoring systems lower recall risk, reduce insurance premiums, and accelerate the path to certified status. In the MEA region, where gluten and lactose intolerance affects up to 80% of the population in parts of Africa and the GCC, this combination of health prevalence and regulatory-readiness infrastructure represents a strategically underserved frontier.

Investment Considerations

For investors, the gluten-free AI opportunity sits at the intersection of three durable secular trends: rising chronic dietary condition prevalence, the industrialization of AI across consumer packaged goods, and ESG-driven supply chain transformation. Companies with proprietary AI formulation platforms — NotCo's 'Giuseppe' licensing model being the most architecturally distinctive — are positioned to generate platform-level returns beyond their own product portfolios. General Mills, Mondelēz International, and Nestlé offer exposure to AI-led productivity gains within large-cap consumer staples structures, while pure-play AI nutrition platforms such as Viome and Spoon Guru represent higher-risk, higher-upside bets on personalized health monetization. Key risks include specialty ingredient price volatility, regulatory fragmentation across jurisdictions, and the substantial R&D capital required to achieve consistent gluten-free formulation quality at scale.

About the Report

AI Impact on Gluten Free Products - BCC Pulse Report (AIT193A) provides qualitative strategic analysis of AI adoption across the gluten-free food value chain, covering technology deployment, competitive positioning, investment activity, regional dynamics, and emerging innovation across key global markets.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

CONTACT: BCC Research LLC
50 Milk St., Ste. 16, Boston, MA 02109
press@bccresearch.com  |  +1 781-489-7301
www.bccresearch.com